Literature DB >> 3830721

The disposition and elimination of stereoisomeric pairs of thioridazine 5-sulfoxide in the rat.

P W Hale, S Melethil, A Poklis.   

Abstract

The disposition and elimination of 2 stereoisomeric forms of thioridazine 5-sulfoxide (ring sulfoxide) were followed for 72 hr in male Sprague-Dawley rats following the administration of a single 40 mg/kg intraperitoneal dosage. The distribution half-lives for the fast (RSF) and slow (RSS) eluting ring sulfoxides in serum were 4.40 and 3.23 min, respectively. Elimination half-lives were 1.79 and 2.06 h. Both RSF and RSS were distributed throughout the tissue in equal amounts based on HPLC analysis of the tissues. Both isomers were found in lung tissue at concentrations 10 times that for other organs. Elimination of the ring sulfoxide was complete by 72 hours except in the brain, lung and kidney. The brain, heart, liver and kidney exhibited periodicity, or recycling of both RSF and RSS during the elimination phase. Release of RSF and RSS from myocardial tissue was slower than that for all other tissues. Excretion of unchanged thioridazine 5-sulfoxide occurred via renal, and to a lesser extent, biliary mechanisms. The biliary excretion pattern suggested an enterohepatic circulation of both isomers. These results indicate a lack of stereoselectivity in the disposition and clearance of the two ring sulfoxide isomers in the animal model; results that mirror those seen in man.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3830721     DOI: 10.1007/BF03189762

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  26 in total

1.  Plasma levels and half lives of thioridazine and some of its metabolites. I. High doses in young acute schizophrenics.

Authors:  F A Vanderheeren; R G Muusze
Journal:  Eur J Clin Pharmacol       Date:  1977-01-03       Impact factor: 2.953

2.  Comparison of TPS-23 and thioridazine in chronic schizophrenic patients.

Authors:  A A Sugerman
Journal:  Curr Ther Res Clin Exp       Date:  1965-09

3.  A double-blind comparison of the therapeutic efficacy of mesoridazine versus chlorpromazine.

Authors:  H Freeman; M R Oktem; N Oktem
Journal:  Curr Ther Res Clin Exp       Date:  1969-05

4.  Quantitative determination of thioridazine and nonconjugated thioridazine metabolites in serum and urine of psychiatric patients.

Authors:  E Mårtensson; G Nyberg; R Axelsson; K Serck-Hansen
Journal:  Curr Ther Res Clin Exp       Date:  1975-11

5.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

6.  Thioridazine 5-sulfoxide diastereoisomers in serum and urine from rats and man after chronic thioridazine administration.

Authors:  P W Hale; A Poklis
Journal:  J Anal Toxicol       Date:  1985 Sep-Oct       Impact factor: 3.367

7.  Comparison of the effects of chronic haloperidol treatment on A9 and A10 dopamine neurons in the rat.

Authors:  F J White; R Y Wang
Journal:  Life Sci       Date:  1983-02-28       Impact factor: 5.037

8.  Species differences in pulmonary N-oxidation of chlorpromazine and imipramine.

Authors:  Y Ohmiya; H M Mehendale
Journal:  Pharmacology       Date:  1984       Impact factor: 2.547

9.  Thioridazine and its metabolites in post mortem blood, including two stereoisomeric ring sulfoxides.

Authors:  A Poklis; C E Wells; E C Juenge
Journal:  J Anal Toxicol       Date:  1982 Sep-Oct       Impact factor: 3.367

10.  Thioridazine-induced torsade de pointes. Successful therapy with isoproterenol.

Authors:  A J Kemper; R Dunlap; D A Pietro
Journal:  JAMA       Date:  1983-06-03       Impact factor: 56.272

View more
  1 in total

1.  The biotransformation of thioridazine to thioridazine 5-sulfoxide stereoisomers in phenobarbital induced rats.

Authors:  P W Hale; A Poklis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Oct-Dec       Impact factor: 2.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.